Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 11661422
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Incyte Corporation
    Inventors: Kai Liu, Brent Douty, Daniel Levy, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230151005
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: September 20, 2022
    Publication date: May 18, 2023
    Inventors: Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu
  • PYRAZOLOQUINOLINE KRAS INHIBITORS
    Publication number: 20230143938
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 11, 2023
    Inventors: Wenyu ZHU, Xiaozhao WANG, Wenqing YAO
  • QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230144051
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: October 13, 2022
    Publication date: May 11, 2023
    Inventors: Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230146129
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 27, 2022
    Publication date: May 11, 2023
    Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20230121440
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: July 18, 2022
    Publication date: April 20, 2023
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
  • TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20230124485
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: December 8, 2022
    Publication date: April 20, 2023
    Inventors: Heeoon Han, Le Zhao, Wenqing Yao, Xiaozhao Wang
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230114765
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 13, 2022
    Publication date: April 13, 2023
    Inventors: Zhenwu Li, Zhiyong YU, Jeremy Roach, Gia Hoang, Bin HU, Gencheng Li, Rory McAtee, Ken Mukai, Rocco Policarpo, Robert Susick, Xiaozhao Wang, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230100875
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 30, 2023
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11613536
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 28, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11608337
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11607416
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • PD-L1/STING conjugates and methods of use
    Patent number: 11596692
    Abstract: The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 7, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Zhenwu Li, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11591329
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230056631
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 6, 2022
    Publication date: February 23, 2023
    Inventors: Pei Gan, Jeffrey Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Xiaozhao Wang, Wenqing Yao
  • PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
    Publication number: 20230043959
    Abstract: The present invention provides piperidin-4-y1 azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: February 17, 2022
    Publication date: February 9, 2023
    Inventors: Taisheng Huang, Chu-Biao Xue, Hui-Yin Li, Qun Li, Anlai Wang, Lingquan Kong, Hai Fen Ye, Wenqing Yao, James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11572366
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: February 7, 2023
    Assignee: Incyte Corporation
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11566026
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: January 31, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11566028
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: January 31, 2023
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Jeremy Roach, Wenqing Yao
  • IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20230024173
    Abstract: The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: July 29, 2022
    Publication date: January 26, 2023
    Inventors: Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo